According to a recent LinkedIn post from Cleerly, the company plans a presence at the American College of Cardiology’s ACC.26 conference in New Orleans from March 28–30. The post highlights demonstrations of its AI-powered platform for coronary CT angiography, emphasizing quantitative assessment of coronary artery disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post suggests that Cleerly will showcase 3D coronary artery modeling and color-coded plaque analysis aimed at supporting clinical decision-making. For investors, visibility at a major cardiology meeting could help drive clinician adoption, support longer-term commercial traction, and reinforce Cleerly’s positioning in the growing cardiac imaging and AI-enabled diagnostics segment.